Jazz falls on FDA panel vote

Jazz Pharmaceuticals Inc. (NASDAQ:JAZZ) fell $2.27 (22%) to $7.96 on Monday after FDA's Arthritis Drugs and Drug Safety and Risk Management committees voted 20-2 on Friday that the benefit/risk profil...